Every year we assume responsibility for the well-being of millions of patients. We offer lifesaving and life-sustaining products and therapies. In their development, we take into account different social and regulatory requirements and adapt them to different health care systems. This enables us to meet the growing global demand for innovative, high-quality therapies. In 2021, we had more than 90 own production sites and operated in more than 90 countries with own subsidiaries. Numerous national and international research projects and studies are carried out in our business segments. In this way, we investigate and develop new treatment standards, improve current standards, for example by studying the side effects of pharmaceuticals by biological sex or age group, and facilitate best practice exchange of our health care professionals. Further, in our hospitals in Spain and Germany, various approval studies for pharmaceuticals are conducted. We report in detail on our clinical study management in the Digital transformation and innovation chapter.
Our products are often used to treat people who are suffering from serious or chronic diseases. Our task is to ensure the safety and quality of our products and services and to meet the highest safety and quality standards for all processes and therapies. Information on our health care markets can be found in the section Health care industry of the Group Management Report 2021.
Our range of products and services includes a comprehensive network of hospitals, modern dialysisDialysisForm of renal replacement therapy where a semipermeable membrane – in peritoneal dialysis the peritoneum of the patient, in hemo dialysis the membrane of the dialyzer – is used to clean a patient’s blood. procedures and post-acute care – such as rehabilitation – and high-quality drugs and medical products. Our portfolio also includes digital health services, advanced therapies, and the expansion of primary care in emerging and developing countries. The main focus is on the quality of our products and of the medical care we provide our patients.
In 2021, access to health care and medicine was again hampered by the COVID-19 pandemic. In these challenging times, we have taken on our special responsibility as part of the healthcare system with extensive measures, which we already started in 2020. Further information can be found in this chapter, section Health care delivery during the COVID-19 pandemic.
Our approach
Fresenius’ long-term goal is to further develop the company’s position as one of the leading international providers of health care products and services. In recent years, we have expanded our company along our value chain – increasing the global availability of our products and services.
The constant development of our products and services allows us to take advantage of growth opportunities. We guarantee our patients high-quality, comprehensive health care with our products and in our own facilities, allowing them to benefit from medical progress.
Our core business focuses on ensuring that as many people as possible worldwide are able to participate in this progress. We consider health equity in our efforts to increase access to care worldwide and to support the development of sustainable health care systems. This means striving to make treatment and health education available to those in need, irrespective of age, income distribution, race or ethnicity, or education. This ambition is also reflected in our commitment to society.
Medical initiatives and projects to improve access to health care
The four business segments set their focus oin their contribution to improving access to health care worldwide. The newly appointed Head of Transplantation Medicine of Fresenius Medical Care leads the business segment’s worldwide efforts to expand access to and understanding of transplant medicine. The Fresenius Medical Care Foundation collaborates with several leading organizations to raise awareness and provide support to people living with kidney disease. Through these partnerships, the foundation supports efforts to make sure that every eligible person who needs a kidney, receives one. As an example of this collaboration, in 2021 the business segment finalized a US$106,000 grant to the United Network of Organ Sharing (UNOS). Through the investment, Fresenius Medical Care is helping UNOS learn more about ways to improve transportation and logistics for organ donation. With the aid organization Friedensdorf International, Fresenius Helios offers free treatment for children from crisis regions in German Helios clinics.
Fresenius Medical Care
Fresenius Medical Care recognizes the importance of improving access to health care and is working to provide affordable treatment to a growing number of patients worldwide. The business segment’s Global Medical Office leadership team frequently discusses how to best manage this topic as part of the medical strategy. The focus is on both improving access to care and level-of-care outcomes. Fresenius Medical Care considers, for example, barriers to access such as cost and ease of travel to the dialysis clinics, lack of education on kidney disease, and unsustainable health care systems in developing countries. The business segment aims to increase the number of patients on home dialysis and has improved the digital offering to make it easier for patients to access its services. Additionally, the development of renal care infrastructure is an important part of the company's strategy. This includes continuing to expand its network of dialysis clinics, for example. Fresenius Medical Care also has processes in place that allow patients’ treatment to continue during crisis and emergency situations.
Home dialysis allows Fresenius Medical Care to expand the health care capacity, increasing the number of patients that can be treated by a dialysis clinic. In addition, by facilitating treatment for patients living in more remote regions, the business segment aims to widen its geographical reach and reduce patient travel.
Fresenius Kabi
Fresenius Kabi is committed to improving patients’ quality of life. The business segment’s product portfolio targets critically and chronically ill patients. It comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilarsBiosimilarsA biosimilar is a drug that is “similar” to another biologic drug already approved., Fresenius Kabi focuses on autoimmune diseases and oncology. Within transfusion medicine and cell therapies, the business segment offers products for collection of blood components and extracorporeal therapies. With its comprehensive range of generics and biosimilars products, Fresenius Kabi provides access to modern, high-quality, and affordable therapies for patients. Generics and biosimilars are cost-effective alternatives to originator drugs. They help to lower the price of treatments and thus reduce the burden on healthcare systems, e. g., in the United States or in Europe. Further information is provided in the Group Management Report 2021.
Fresenius Kabi is in regular exchange with the Access to Medicine Foundation with regard to the Antimicrobial Resistance (AMR) Benchmark. In this benchmark, selected manufacturers of generic drugs are regularly evaluated in the categories Appropriate Access, Stewardship, and Responsible Manufacturing. Fresenius Kabi is evaluated in the AMR Benchmark as an important manufacturer of generic antibiotic products. The business segment scores consistently highly and has improved its rating in the AMR Benchmark 2021 compared to the previous evaluation. In the category of generic drug manufacturers, Fresenius Kabi performs above average overall, thus recognizing the business segment’s efforts with regards to AMR, in particular its performance in the categories Stewardship and Responsible Manufacturing. In addition, Fresenius Kabi has been a member of the AMR Industry Alliance since 2020 and has been actively involved in the association’s governing bodies since 2021. As a member, Fresenius Kabi strives to follow the guidelines of the Common Antibiotic Manufacturing Framework (CAMF) to further improve its environmental management in this area. For example, the CAMF includes limits on the discharge of wastewater contaminated with antibiotic residues. Fresenius Kabi has started to implement appropriate measures and controls for the discharge of wastewater at its 18 antibiotic-producing or antibiotic-using sites.
Fresenius Kabi also fosters access of patients to clinical nutrition. Malnutrition can have a negative impact on patients’ health and well-being as well as resulting in increased costs for health care systems. That is why the business segment is engaged in the Medical Nutrition International Industry Group (MNI), which focuses on raising awareness of the need for clinical nutrition, e.g., for cancer patients. Clinical nutrition also plays a role in the treatment and recovery of COVID-19 patients. Fresenius Kabi, for instance, extended its online offering of relevant information on nutrition and its effect on the recovery of COVID-19 patients in 2021.
Fresenius Helios
Fresenius Helios’ acute care hospitals, outpatient clinics and other health care facilities offer the full range of medical services. Our international hospital network enables Fresenius Helios to transfer knowledge between health care systems in Germany, Spain and Latin America with regard to affordable health care of high-quality, and with very high standards of service and patient experience. In 2021, this international network enabled an intensive knowledge exchange on the treatment of COVID-19 patients in order to improve treatment outcomes.
Fresenius Vamed
Fresenius Vamed is active worldwide in the planning and construction of healthcare buildings with the aim of serving patient health and improving access to healthcare services. Fresenius Vamed also provides operational management services for acute and post-acute care facilities, prevention centers, and elderly care homes, as well as technical services with a focus on building, construction, and medical technology, sterile goods supply, information and communication technology, and infrastructure and business services. This enables Fresenius Vamed to provide access to high-quality medical care for a growing number of people.
Patient safety is directly dependent on the quality of the treatments, care, or products used and indirectly on the provision of operational management services. Fresenius Vamed’s main goal is to give people around the world access to health care services at all levels of care.
Progress and Measures 2021
Product and service portfolio
There were no significant changes in the Fresenius Group’s product and service portfolio in the reporting year 2021. Under the influence of the ongoing COVID-19 pandemic, the primary objective was to ensure patient care and access to our products, services and health care facilities.
In 2021, Fresenius Medical Care provided home therapy to more than 54,000 peritoneal and hemodialysis patients globally. In 2017, the business segment set itself the goal of performing over 15% of treatments in the United States in a home setting by 2022. This goal was achieved in the third quarter of 2021 and the business segment set a new target in 2022. Globally, the number of its home dialysis patients increased by about 10,000. In the United States alone, Fresenius Medical Care educated more than 56,000 people living with chronic kidney disease or end-stage kidney disease about home dialysis options in 2021. The business segment did this with the support of more than 180 kidney care experts.
The business segment further adapted its activities to the requirements of the COVID-19 pandemic in the reporting year. Numerous elective or less time-critical treatments were again postponed in the hospital setting. Fresenius Kabi thus stepped up its efforts to secure the supply of healthcare facilities with drugs and medical devices for treatment of intensive care and COVID-19 patients. In addition, the business segment has adapted its activities, e. g., in distribution, to the respective specifications in place to control the spread of infection in the various countries. Through numerous webinars and online offerings, Fresenius Kabi has worked to educate healthcare professionals and patients with training and education on relevant topics such as inflammatory diseases, and clinical nutrition in the care of critically and chronically ill patients, cancer patients or chronic kidney disease patients.
Fresenius Kabi wants to be the preferred partner for physicians and caregivers responsible for the treatment of critically and chronically ill patients. To this end, the Fresenius Kabi Vision 2026 has been developed in the reporting year and adopted in the fourth quarter of 2021. Through Vision 2026 the business segment has defined an overarching direction for Fresenius Kabi with three well-defined growth vectors: broaden its biopharmaceutical offering, development and global roll out clinical nutrition, expand in MedTech, and build resilience in its volume-driven I.V. business. Information on Vision 2026 is provided in the Group Management Report.
Fresenius Kabi is constantly expanding its product range to provide high-quality and affordable health care to more patients. The business segment is expanding product availability in established markets as well as in new and emerging markets and has launched new products in 2021.
For example, a cooperation between the business segments Fresenius Kabi and Fresenius Medical Care in Poland has expanded the availability of a clinical nutrition product. Many patients with chronic kidney disease now have access to Fresenius Kabi's product Ketosteril, which is used to treat insufficient protein metabolism in their indication. Since March 2021, the cost of the treatment has been reimbursed by the Polish Health Fund, which significantly improves access for patients in Poland. Furthermore, Fresenius Kabi aims to expand access to this product to several other European countries.
Fresenius Kabi also began a collaboration with Fundación SEFAC in 2021 to raise awareness of malnutrition in people over 65. SEFAC is the Spanish Society for Clinical, Family, and Community Pharmacy. The aim of the collaboration is to provide local pharmacists with the necessary information to recognize and treat malnutrition or impending malnutrition in elderly patients. To this end, information material will be made available in pharmacies to highlight the impact and risk of malnutrition. In addition, pharmacists will be made more aware of malnutrition and the importance of early detection for the well-being of patients.
In 2021, Fresenius Helios closed the acquisition of the fertility service provider Eugin Group. Following closing of the acquisition, the company has been consolidated in the financial reporting since April 1, 2021, and will be integrated into the non-financial reporting as of 2022. Further information on Eugin Group is included in the Fresenius Group Annual Report. In 2021, the business segment conducted further strategic portfolio adjustments, which are also described in the Group Annual Report 2021.
The improvement of therapeutic measures based on clinical studies outcomes and the increasing use of telemedical services are explained in detail in the chapter Digital transformation and innovation of this report.
Fresenius Vamed is one of the leading private providers of post-acute care in Central Europe, thus strengthening access to the relevant services, especially in the rehabilitation segment. In 2021, outpatient rehabilitation services were expanded. The outpatient offerings are easy to access and enable in-service utilization of medically necessary rehabilitation services. Existing facilities were expanded by therapeutic offers for additional indications. After numerous rehabilitation facilities were temporarily closed in 2020 due to the COVID-19 pandemic, business operations were largely uninterrupted in 2021. In order to ensure safe access to our health care services for our patients and employees in the wake of the COVID-19 pandemic, comprehensive prevention concepts were drawn up based on regulatory provisions, and measures were implemented and adapted in line with epidemiological developments. In addition, a Coronavirus Crisis Team, which meets regularly, has been installed to check the validity and application of existing preventive measures.
Patient support in crisis and emergency situations
As a health care Group, we have to be crisis-proof and respond flexibly in all areas: it is our task to enable unrestricted access to our services and seamless care for patients even under difficult conditions. To ensure this, we have established high-performance as well as resilient emergency systems and programs in our business segments.
Fresenius Medical Care’s goal is to continue to provide access to health care under difficult circumstances, for example in the case of a health crisis or natural disaster. The business segment has dialysis clinics in many regions of the world with diverse geographic, social, and economic conditions, serving a vulnerable population of patients who need regular dialysis treatment multiple times a week. To allow the business segment to continue treating its patients in extreme conditions, it has developed an emergency response system comprising regional disaster response teams. These teams seek to ensure that treatments continue under difficult circumstances. For example, in February 2021, a team assisted patients affected by extreme weather in Texas that caused a water shortage. More than 160 of the business segment’s dialysis clinics were forced to temporarily close as a result, affecting about 5,000 patients. The disaster response teams brought in generators and water tankers to assist in getting clinics operational. Additionally, Fresenius Medical Care provided hospitals with dialysis equipment and supplies to help manage the surge of patients seeking treatment.
Furthermore, the business segment regularly tests the emergency response procedures to assess service safety and continues to donate funds, dialysis machines, and medical supplies to organizations that require support.
Fresenius Kabi has a crisis team for emergency situations which is summoned immediately after an event that could lead to a crisis occurs. The crisis team comprises members of the Management Board, key staff units, and other relevant functions of the business segment and initiates necessary measures, coordinates the company’s activities, and monitors the measures initiated. Crisis situations are considered to be unforeseen events that may, e. g., have an impact on the company or the public. During the COVID-19 pandemic, the crisis team met to coordinate measures to ensure the supply of vital medicines to patients.
In the hospital sector, there are legal requirements for how care is to be organized in the event of an emergency. Therefore, hospitals and health care facilities have dedicated emergency plans to respond immediately to incidents that might be critical for patients. These encompass, among others, evacuation plans, emergency systems in case of interruption of power or water supply, or plans to respond to impacts on local infrastructure, like flooding. Emergency power generators ensure that operations or vital therapies, such as artificial respiration, can continue even in the event of a power failure. In 2021, incidents occurred in Germany and Spain, such as extreme weather events, that impacted the respective local hospital infrastructure and patient care. Patients were not harmed by these events. Incidents were assessed, together with the local authorities, and necessary evacuation measures or remediation measures were implemented.
Fresenius Helios donated critical vaccines to the emergency teams and the population after the extreme weather events in July 2021. To keep the health risks of the emergency teams and the populations as low as possible, Helios handed over 5,000 vaccination doses against tetanus to the DRK (Deutsches Rotes Kreuz).
At Fresenius Vamed, a structured crisis management system takes immediate effect in critical situations. It comprises the Management Board, key staff units, and the management teams of the lead companies. The crisis team meets as soon as an incident becomes known and initiates all necessary measures. Like Fresenius Helios, Fresenius Vamed’s facilities have emergency and outage concepts and crisis communication plans in place, which have been drawn up together with the local emergency units. Beyond that, Fresenius Vamed ensures all necessary prerequisites to ensure the safety of systems and infrastructure, not only for its own facilities but also for those hospitals, for which the company provides facility management services. These measures have increased the speed of response to individual COVID-19-related incidents and thus made it possible to provide facilities that were particularly affected with additional protective equipment. In 2021, the VAMED clinic Hagen-Ambrock was affected by the extreme weather situation in Germany. Our emergency plans were activated, and the local infrastructure was secured, for example by emergency power generators and submersible pumps. The care of our patients was thus ensured. In our other regions affected by extreme weather situations, no clinic operation was impacted.
Health care delivery during the COVID-19 pandemic
The COVID-19 pandemic again posed continued extraordinary challenges to the global health care system in 2021. For Fresenius as a health care Group and as a company with many employees and a great deal of patient contact, pandemic protection and prevention is essential. Emergency management plays a key role in this: it enables us to maintain the care of all patients in our health care facilities and ensure the supply of medicines. Based on the legal requirements and regulatory recommendations for the COVID-19 pandemic, our business segments implemented measures in response:
In 2021, the fallout from the COVID-19 pandemic continued to present the business segment with extraordinary challenges. These were exacerbated by the fact that acute kidney injury is common in critically ill COVID-19 patients, and that patients have a high risk of complications should they contract the virus. Patients and staff entering dialysis clinics are screened for the virus and given personal protective equipment. Fresenius Medical Care also encouraged patients to get vaccinated. In addition, Fresenius Medical Care has set up isolation centers and treated more than 17,000 patients infected with COVID-19 in North America.
To broaden the contribution to the fight against COVID-19, the business segment donated €250,000 to UNICEF to support its vaccination initiative in about 140 countries. UNICEF will put this money towards measures aimed at protecting teachers and medical workers against the COVID-19 virus. This in turn should support the care and education of children impacted by the pandemic. The business segment provided hundreds of acute dialysis devices and further supplies to hospitals for emergency treatment.
Despite the increased safety measures, it was able to continue producing and delivering life-saving products, even when operations and supply chains were hampered by global restrictions.
Demand for some of Fresenius Kabi’s drugs and medical devices has increased significantly due to the COVID-19 pandemic. For example, the business segment saw an increased demand for its infusion pumps and respective disposables in 2021 and an ongoing high demand for clinical nutrition. Fresenius Kabi reacted to this demand early, using all suitable capacities to increase production volume for these products. In addition, Fresenius Kabi’s crisis team, which was set up at the beginning of the pandemic, is continuously coordinating the efficient manufacturing and supply of essential drugs needed for the management of critically ill COVID-19 patients. Fresenius Kabi continued its activities in response to the ongoing COVID-19 pandemic and adapted them to the changing environment. The focus in the reporting year, in view of the volatility of the procurement markets, was on supply capability in order to ensure the supply of vital medicines and medical devices for patients. The business segment closely monitored the availability of materials required for the manufacture of products to ensure the best possible availability, e. g., through increased inventories as applicable or higher safety stocks for selected raw materials essential for the production of products, as well as ongoing alternative supplier qualifications. In 2021, Fresenius Kabi was able to mitigate supply bottlenecks for sourced products and avoided significant effects on the supply of vital drugs and medical devices to patients.
In addition, Fresenius Kabi actively contributed to the European Commission’s structured dialogue on security of medicines supply initiated in 2021. The dialogue engaged representatives from the pharmaceutical industry, health care professionals and patients, Member States of the European Union as well and national competent authorities with responsibility for medicines authorization. The goal of this forum was to identify different potential vulnerabilities of pharmaceutical supply chains and consequent measures aimed at strengthening their resilience, in order to ensure the security of supply, without compromising affordability of medicines.
Measures taken at our Fresenius Helios’ hospitals in 2021 were carried out in close, continuous consultation with the respective crisis team at Group level and the crisis teams or task forces of the clinics as well as the central and local hospital hygiene departments. As of March 2021, the numbers of intensively managed COVID-19 patients in the Helios hospitals dropped significantly and a return to normal operations was initiated. By mid-2021, elective procedures were suspended only in isolated cases, depending on the utilization of the respective intensive care unit by COVID-19 patients. In what was referred to as the fourth wave, the number of COVID-19 patients again increased noticeably from October 2021, with recognizable hotspots in the German states of Saxony and Bavaria. Here, elective operations had to be postponed again in isolated cases. Since June 2021, the number of COVID-19 patients in our German clinics has been published on the website of the business segment (German language). Further information is provided regarding the intensive care capacity and treatment of the patients.
In the reporting year, it was possible to draw on the experience gained in 2020 and adjust staffing and structural capacity depending on the pandemic situation. At Helios Germany, for example, the number of intensive care beds was increased again to over 1,300 at the start of the fourth wave in fall 2021, following a comparatively relaxed overall situation in the summer. Helios Germany cared for about 30,000 patients with a COVID-19 infection in 2021, more than 8,000 of whom required intensive care. About 5,000 patients died in our hospitals with or due to a COVID-19 infection.
At our hospitals in Spain and Latin America, more than 20,000 patients have been hospitalized in 2021. The mortality rate was 12% in 2021.
The use of social media to educate and inform about COVID-19 has been successful in Germany and Spain. For the German sites, Helios published messages on the pandemic, testing procedures and vaccinations, which were widely shared. Helios Spain uses its social media channel to provide written information or videos on the most urgent questions, like hygiene, vaccines, or even the impact on family life, as well as information regarding the impact on hospitals appointments and the availability of COVID-19 tests in our centers. Our dedicated hotlines were well received by the general public, and we again received a high number of calls.
COVID-19 testing and Helios vaccination campaign
In April 2021, Fresenius Helios launched its mobile service in Germany for nationwide, rapid, and safe COVID- 19 testing in what are referred to as coronavirus “testmobiles”. There, citizens can have a rapid test carried out free of charge and receive a test certificate. In addition, Helios Germany has vaccinated approximately 424 million doses against coronavirus trough a comprehensive vaccination program at its hospitals and integrated health care facilities from April to the end of December 2021. Helios also supported the German government’s #HierWirdGeimpft vaccination campaign with more than 170 facilities. In addition to hospital bed occupancy rates, which Helios has been publishing since summer 2020, the company has also been reporting data on the vaccination status of inpatients suffering from COVID-19 since September 2021. This includes cases in intensive care units. All information is updated weekly at https://www.helios-gesundheit.de/qualitaet/impfstatus.
In the hospitals in Spain, COVID-19 screening protocols have been carried out in patients before their hospital admission and for prevention and management of nosocomial infection with COVID-19. In addition, Helios Spain has been very active in conducting COVID-19 tests for the general public.
For all managed and owned health care facilities, Fresenius Vamed created catalogs of measures in which the pandemic experiences in Austria, Germany, the Czech Republic, the United Kingdom, and Switzerland were collected; these catalogs are updated regularly. As a result, our health care facilities were able to remain open, subject to the respective regulatory requirements. The experience gained will continue to be incorporated into risk management in the future and will help Fresenius Vamed to continuously improve its processes and actions. Furthermore, a 24 / 7 information hotline as well as comprehensive and continuously updated information on the Fresenius Vamed intranet “Corona Infocenter” are available to Fresenius Vamed staff. In Germany and Austria, a small number of COVID-19 cases occurred in the nursing facilities, except for two facilities in Germany, where larger numbers of COVID-19 cases were reported.
The prevention measures, such as the 3G rule, testing offers for residents and employees, mandatory masks, access restrictions, etc., have been and are being implemented accordingly or adapted to the situation.
Please refer to the Notes to the Consolidated Financial Statements on pages 312 f. for further information on assistance programs provided by various governments in the form of reimbursement payments and funding in connection with the COVID-19 pandemic.
Promotion of health awareness
The measures to promote health awareness in 2021 were again dominated by COVID-19. During the coronavirus pandemic, our patients have been continuously informed about the observance of hygiene rules in our health care facilities. At Fresenius Helios, the range of video consultation hours has been expanded. In addition, learning and information videos have been made available on our country websites. Fresenius Kabi promotes awareness and scientific exchange with health care professionals on clinical nutrition during patient treatment, e.g., through webinars or during congresses. In 2021, the business segment held various webinars focusing on the use of biosimilars in inflammatory diseases, the impact of pre-habilitation in oncological surgery, and on the topic of clinical nutrition.
Fresenius Kabi supports health care professionals and patients by offering training and providing information materials. In the field of biosimilars, the business segment develops medical training including webinars that focus on the concept of biosimilars, the appropriate nutrition and autoimmune conditions. Fresenius Kabi offers KabiCare, a comprehensive support program that helps health care professionals and patients to live with chronic diseases, for example, autoimmune conditions. KabiCare provides information about the disease and products, training including injection training, coaching tools, nutrition information, and other practical tips to help cope with the disease.
Fresenius Kabi supported the International Alliance of Patient Organizations for Chronic Intestinal Failure and Home Artificial Nutrition (PACIFHAN), that federates patient organizations in 10 countries around the world, for the third time in 2021 with the objective to raise awareness of home artificial nutrition and share experiences from patients around the world living with artificial nutrition. PACIFHAN is promoting the World Home Artificial Nutrition Day every year in October.
Social commitment
The ambition to provide access to health care for as many people as possible worldwide and to continuously improve it is pursued by our business segments through their social commitment. Fresenius Medical Care’s social commitment focuses on regional and local initiatives that support the interests of kidney patients. This includes emergency aid in crisis situations, e.g., through donations of dialysis machines and medical supplies, as well as long-term measures such as Kidney Kid, an initiative to educate children about kidney health at an early age.
Fresenius Kabi and Fresenius Helios actively support social causes through donations or employee community engagement, among other things. In 2021, Fresenius Kabi, e.g., donated personal protective equipment, i.e. face masks, and disinfection gel in Tunisia to support the community during the ongoing coronavirus pandemic. Fresenius Kabi, e.g., made a donation to “KinderEngel RheinMain e.V.” association in Germany to support it in its work with children and young people with serious or life-shortening illnesses and their families in their everyday lives.
Fresenius Helios aims to improve people’s health and well-being, promoting healthy lifestyles and participating in various social initiatives, being fully aware of the direct responsibility as a hospital operator for the current challenges facing people and the planet, as well as its ability to contribute to sustainable development. Helios Spain is committed to helping to overcome the national emergency caused by the pandemic, collaborating with all the health authorities, working as a team with a common goal, coordinating all the human and material resources of the own health care network, and, in short, doing the utmost to try to help as many people as possible.